Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.96 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.96 |
| ▸ | HPGD | P15428 | 7/20 | 0.96 |
| ▸ | ESR1 | P03372 | 1/20 | 0.96 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.96 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.96 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | GGT1 | P19440 | 1/20 | 0.96 |
| ▸ | BLM | P54132 | 1/20 | 0.96 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 1/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspirin SCHEMBL10456693 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL29350479 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL1353 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL1331740 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL7580 | 0.98 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL7762350 | 0.96 | KDM4E (0.96) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL21722099 | 0.96 | KDM4E (0.96) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL20484785 | 0.96 | KDM4E (0.96) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL21488922 | 0.96 | KDM4E (0.96) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL2584555 | 0.96 | KDM4E (0.96) | KDM4EHSD17B10ALDH1A1HPGDESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114933758-A | Quantum dot thin film material with gas-sensitive performance and application thereof | 江苏烨湫传感科技有限公司 | 2022-08-23 | — | — | CN | claimed |
| CN-113105817-B | Side-chain dopamine functionalized polyurethane coating and preparation method and application thereof | 华南理工大学 | 2022-03-25 | — | — | CN | claimed |
| CN-113105817-A | Side-chain dopamine functionalized polyurethane coating and preparation method and application thereof | 华南理工大学 | 2021-07-13 | — | — | CN | claimed |
| CN-108779290-B | Metal-based hydrogen sulfide scavengers and methods of making the same | 通用电气(GE)贝克休斯有限责任公司 | 2021-03-12 | — | — | CN | claimed |
| CN-108450480-B | Agricultural bacterial bactericide and application thereof | 河南省农业科学院植物保护研究所 | 2020-12-18 | — | — | CN | claimed |
| CN-108779290-A | Hydrogen sulfide scavenger based on metal and preparation method | 通用电气(GE)贝克休斯有限责任公司 | 2018-11-09 | — | — | CN | claimed |
| CN-108450480-A | A kind of agricultural bacterium fungicide and its application | 河南省农业科学院植物保护研究所 | 2018-08-28 | — | — | CN | claimed |
| CN-101456816-B | One-step synthesis method of aspirin copper | UNIV YANBIAN | 2012-05-30 | — | — | CN | claimed |
| CN-102049049-A | Medical composition containing aspirin salt and stanin medicaments | DINGHAO WANG | 2011-05-11 | — | — | CN | claimed |
| CN-101668543-A | TGF-beta agonists and other agents to reduce side effects | TCP INNOVATIONS LTD | 2010-03-10 | — | — | CN | claimed |
| CN-101456816-A | One-step synthesis method of aspirin copper | UNIV YANBIAN (CN) | 2009-06-17 | — | — | CN | claimed |
| CN-101316509-A | Compounds and relative use for the control of phytopathogens | ISAGRO RICERCA SRL (IT) | 2008-12-03 | — | — | CN | claimed |
| CN-100394177-C | High-efficient liquid-phase chromatographic testing method for copper in aspirin | KUNMING INST OF PRECIOUS METAL (CN) | 2008-06-11 | — | — | CN | claimed |
| CN-1584588-A | High-efficient liquid-phase chromatographic testing method for copper in aspirin | KUNMING NOBLE METAL INST (CN) | 2005-02-23 | — | — | CN | claimed |
| CN-1443536-A | Aspirin compound preparation for resisting inflammation, stopping pain and resisting thrombus | KUNMING INST OF NOBLE METALS (CN) | 2003-09-24 | — | — | CN | claimed |
| US-20030064970-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | NEORX CORPORATION | 2003-04-03 | — | — | US | claimed |
| WO-1998046588-A2 | COMPOUNDS AND THERAPIES FOR THE PREVENTION OF VASCULAR AND NON-VASCULAR PATHOLOGIES | NEORX CORPORATION (US) | 1998-10-22 | — | — | WO | claimed |
| US-4657928-A | Organic copper complexes as radioprotectants | INTERNATIONAL COPPER RESEARCH ASSOCIATION, INC. (US) | 1987-04-14 | — | — | US | claimed |
| CN-119040717-A | Molybdenum alloy, medical implant device and method of making | 上海微创医疗器械（集团）有限公司 | 2024-11-29 | — | — | CN | disclosed |
| EP-0115130-A1 | Pharmaceutical compositions for treating inflammation or arthritis | NATIONAL RESEARCH LABORATORIES (US) | 1984-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064970-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | TGFB1, TGFB2, TEK | PTGS1 178/4885PTGS2 342/4885KDM4E 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.